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Nigrostriatal damage is increased in males relative to females. While estrogen is neuroprotective in females, less is known
about potential protective eﬀects of testosterone in males. We determined if castration enhances neuronal injury to 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP). Castrates or sham-castrated mice were sacriﬁced 1 week followinginjection of MPTP
(4 × 20mg/kg) or saline (n = 11-12/group). The right striatum was immunostained for tyrosine hydroxylase (TH). The left
hemisphere was stained by Golgi Cox to quantify neuronal morphology in medium spiny neurons (MSNs) of the dorsolateral
striatum. MPTP reduced TH, but there was no eﬀect of castration and no interaction. For MSN dendritic morphology, MPTP
decreased the highest branch order and increased spine density on 2nd-order dendrites. Castrated males had shorter 5th-order
dendrites. However,there wasnointeraction between gonadalstatusandMPTP.Thus,castrationandMPTPexert nonoverlapping
eﬀects on MSN morphology with castration acting on distal dendrites and MPTP acting proximally.
1.Introduction
Gonadal steroid hormones are potent modulators of neu-
ronal survival and neuronal morphology [1]. In the adult,
steroid hormones exert activational eﬀects in steroid-re-
sponsive brain regions which include protective eﬀects
against neurodegeneration [2, 3]. However, sex diﬀerences
exist in many neurodegenerative disorders, suggesting that
the male and female brains are not equally responsive to
gonadal steroids.
In this regard, Parkinson’s disease (PD) is a common
neurological disorder that demonstrates a substantial sex
diﬀerence, with a one- to twofold higher incidence in men
[4]. PD results from the progressive loss of dopaminergic
neurons in the substantia nigra pars compacta (SNC; [5]).
Dopaminergic eﬀerentsfrom SNC project rostrally as part of
the nigrostriatal pathway to the dorsolateral striatum, where
they synapse onto medium spiny neurons (MSNs). These
eﬀerents are reduced in PD, leading to a depletion of striatal
dopamine. Gonadal steroids modulate the function of the
nigrostriatal system and are thought to contribute, in part,
to this sex diﬀerence.
In females, estrogen promotes the function of the ni-
grostriatal system by enhancing striatal dopamine release,
increasing dopamine metabolism and altering both do-
pamine receptors and uptake sites [6, 7]. In response to
neurotoxic insult, estrogen is also neuroprotective in the
nigrostriatal system [7]. This has been well demonstrated
using1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
and 6-hydroxydopamine (6-OHDA), neurotoxins which
selectively deplete dopaminergic SNC neurons [8]. In both
models, estrogen attenuates the loss of striatal dopamine and
reduces the loss of SNC dopaminergic neurons [9–15].2 Parkinson’s Disease
In parallel to its eﬀects in the female, estrogen also
modulates nigrostriatal function in males [16, 17]. Estrogen
in males is derived by the local aromatization oftestosterone,
although testosterone can also act as an androgen in the
male brain. Whether testosterone has neuroprotective eﬀects
in the male nigrostriatal system, similar to the eﬀects of
estrogen in the female, is not well-established. After MPTP
in castrated mice, striatal dopamine loss is attenuated by
estrogen but not by testosterone [18, 19].
Previous studies investigating the eﬀects of testosterone
on nigrostriatal function in male rats and mice after 6-
OHDA or MPTP have measured dopamine content and
release [18–21], dopaminergic striatal input [21], and do-
pamine transporter binding [19, 21]. It is unknown whether
testosterone reduces the loss of dopaminergic innervation
to the striatum after MPTP in mice. Ultimately, the
eﬀects of MPTP lesion may also extend beyond the SNC
dopamine neurons themselves. Loss of dopaminergic input
may remodel MSN morphology, and testosterone has poten-
tial to attenuate this MPTP-induced deaﬀerentation. The
current study used castrated and gonad-intact adult male
mice to determine whether testosterone reduces MPTP-
induced deﬁcits in striatal dopamine neurochemistry and
MSN neuronal architecture.
2.Materialsand Methods
2.1. Animals. Forty-ﬁve C57BL/6 adult male mice (8–10
weeks old) were obtained from Charles River Laboratories
(Wilmington, MA). Mice were group-housed on a 12:12
LD photoperiod with access to food and water ad libitum.
Experimental procedures were approved by USC’s Insti-
tutional Animal Care and Use Committee and conducted
in accordance with the NIH Guide for the Care and Use
of Laboratory Animals (DHEW Publication 80-23, revised
1985, Oﬃce of Science and Health reports, DRR/NIH,
Bethesda, MD).
Initially, half of the mice (n = 23) were castrated
(OrchX) via a midline scrotal incision. The other half (n =
22) received sham castrations. As measured by androgen-
sensitive seminal vesicle weight, castration was eﬀective
(187.5 ± 14.2mg in sham males versus 5.6 ± 1.4mg in
castrated males, P<. 05). Two weeks later, half of the mice in
each group received MPTP and half were given saline. MPTP
(Sigma, St. Louis, MO) was dissolved in 0.9% saline and
was administered in 4 injections of 20mg/kg (free-base).ip.
with an interinjection interval of 2 hours. Control mice
receivedequivalentinjections of0.1mL saline. This lesioning
paradigm is a well-established method that leads to ca. 67%
lossofnigrostriatal neuronsand90–95%depletionofstriatal
DA, as reported in previous studies from our laboratories
[22, 23].
One week following MPTP, animals were sacriﬁced
via intracardiac perfusion. This duration is suﬃcient for
MPTP-induced cell death to occur [22]. Mice were deeply
anesthetized with sodium pentobarbital (150mg/kg BW)
and perfused intracardially with 150mL of 0.1M sodium
phosphate buﬀer (PB, pH = 7.4) containing 0.9% NaCl and
0.1% NaNO3. The brains were removed and hemisected. To
allow us to obtain TH and neuronal morphologic measures
in the same animals, the right hemisphere for each brain
was processed for TH immunocytochemistry and the left
hemisphere was processed for Golgi-Cox staining. We are
unaware of any evidence of laterality in striatal damage
after.ip. MPTP injections in the mouse.
2.2. Tyrosine Hydroxylase Immunocytochemistry. The right
hemispheres from each brain were postﬁxed in 4% para-
formaldehyde in PB overnight at 4◦C, thencryoprotected for
5d a y sa t4 ◦C with 20% sucrose in PB. Hemispheres were
rapidly frozen and sectioned coronally at 25μmt h i c k n e s s
through the rostrocaudal extent of the striatum. Sections
were stored in PB with 0.01% sodium azide at 4◦Cu n t i l
processed for TH immunocytochemistry.
Sections through thestriatum at or rostral to theanterior
commissure corresponding to Plates 18–28 of Paxinos and
Franklin [24] were stained for TH. Tissue from mice in
diﬀerent groups was stained at the same time. Sections were
incubated overnight at room temperature (RT) in polyclonal
rabbit anti-TH antibody (1:5000; Chemicon, Temecula,
CA) with 4% normal donkey serum and 0.3% Triton X-
100 in PB. The following day, sections were incubated in
biotinylated donkey antirabbit secondary antibody (1:200;
Jackson Immunoresearch, West Grove, PA) and the avidin-
biotin-horseradish peroxidase complex (Vector Elite Kit;
Vector Laboratories, Burlingame, CA), each for 1 hour
at RT with extensive washes in between. TH-labeled cells
were visualized using NiCl-enhanced 3 ,3-diaminobenzidine
tetrahydrochloride with 0.25% hydrogen peroxide. Sections
were mountedontogelatin-coatedslides, dehydratedinalco-
hols, cleared in xylenes, and coverslipped with Permount.
The relative expression of TH immunoreactivity was
measured in dorsolateral striatum on coded slides by an
observer blind to the treatment group. To ensure that
diﬀerences in staining intensity were due to diﬀerences in
antigen expression, multiple sections from each of the
diﬀerent treatment groups were handled concurrently in
identical staining conditions. Control experiments excluding
either primary or secondary antibody were also carried out
to verify staining speciﬁcity. Three striatal sections rostral
to the anterior commissure (Bregma 0.25-1.25 in [24])
were sampled per animal (n = 8-9animals/group) using
methods previously described by our laboratory [25, 26].
Brieﬂy, striatal sections were digitally photographed at low
magniﬁcation. The dorsolateral quadrant of each striatal
sectionwasoutlined,andTHimmunostaining wasmeasured
in a 1.6mm2 circular region of interest at the dorsolateral
boundary of this quadrant (Figure 1). In previous studies
[25, 26], this region shows the largest decrease in TH
immunostaining after MPTP. The relative optical density
(expressed as arbitrary units within the linear range of
detection) was determined by subtracting the relative opti-
cal density of the corpus callosum as background. This
measurement reﬂects both the area and intensity of TH
immunostaining within the striatum. To ensure that the gray
valuesrepresentedanopticaldensitywithinthenonsaturatedParkinson’s Disease 3
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Figure 1: TH staining in the dorsolateralstriatum. Photomicrographs of TH staining in gonad-intact saline-injected (a) and MPTP-treated
(b)mice.Scalebar=500μm.(c)ThedensityofTHstaininginthedorsolateralstriatumofsaline-injected (clear)andMPTP-treated (shaded)
gonad-intact (black bars) and orchidectomized (white bars) male mice (n = 8–10 mice/group). The bar represents an eﬀect of MPTP
(P<. 05). OrchX: orchidectomized; Sham: sham-orchidectomized.
range ofthe image analysis, aKodak photographicsteptablet
(densityrangeto255ODunits)capturedbytheCCDcamera
was used. Maximal tissue immunostaining relative OD units
did not exceed the relative OD units of the tablet.
2.3. Golgi-Cox Staining. Golgi-Cox staining was performed
on the left hemisphere of each brain using the FD Rapid
GolgiStain Kit (FD NeuroTechnologies, Ellicott City, MD).
Pilot studies using Golgi staining (according to Gomez and
Newman [27]), Golgi-cox staining (according to Gibb and
Kolb [28]), and the rapid Golgi kit (FD NeuroTechnologies)
were conducted to determine an optimal way to visualize
neuronal morphology in our striatal tissue. The rapid Golgi
kit provided the most complete staining of medium spiny
neurons.
The hemispheres were placed in Golgi-Cox solution
containing mercuric chloride, potassium dichromate, and
potassium chromate for 2 weeks, and the solution was
replaced after the ﬁrst 24 hours. The brains were moved
to a cryoprotection solution (GolgiStain Kit) for 48 hours
and then sectioned coronally at 200μmo nav i b r a t o m e
(VibratomeSeries1000).Sectionsthrough therostral-caudal
extent of the striatum were mounted on gelatin-coated
slides. Slides were stored in a humidity chamber overnight
and developed the following day according to the Rapid
GolgiStain Kit protocol. Brieﬂy, slides were rinsed in distilled
water and placed in a developing solution for 10 minutes.4 Parkinson’s Disease
Immediatelyafterwards, theslideswere rinsed, dehydratedin
alcohols, cleared in xylenes, and coverslipped with Cytoseal-
60 mounting medium (Richard-Allan Scientiﬁc).Slides were
stored in the dark at RT until morphological analysis.
MSN morphology was analyzed on coded slides by an
observer blinded to the treatment groups using a Nikon
Eclipse 80i microscope (Nikon Instruments, Inc., Melville,
NY) with motorized stage and MicroFire camera (Olympus
America, Inc., Center Valley, PA). To compare dendritic
morphology after castration and MPTP lesion, the entire
dendritic tree from one primary dendrite was traced under
a 100x oil immersion lens using the Neuron Tracing func-
tion in NeuroLucida (MicroBrightField,Inc., Williston, VT).
Brains with well-diﬀerentiated Golgi-Cox labeling from 5
mice in each experimental group were selected for morpho-
logic analysis; 5 neurons from each mouse were analyzed.
Morphologic data from the 5neurons/mouse were averaged
to provide a single data point for each animal used in
statistical comparison (n = 5/group). MSNs selected for
analysis were located in the dorsolateral quadrant of the
striatum at or rostral to the level of the anterior commissure
(Plates18–28of[24]).SelectedMSNswerefullyimpregnated
with Golgi stain and had clearly visible spines with minimal
or absent obstruction by neighboring Golgi-stained cells or
blood vessels. Morphometric analysis was conducted using
NeuroExplorer software (MicroBrightField, Inc.). Brieﬂy,
each dendritic segment was assigned a branch order with the
dendriticsegment proximal tothe soma identiﬁedas the ﬁrst
branch order. Dendriticlengths, number ofspines, and spine
density were computed for each branch order. All dendrites
subject to morphologic analysis had at least 3 branch orders.
However, because not all dendrites had 4th- and 5th-order
branches, the variability in dendritic length increased at
higher branch orders. In addition, total spine density and
total dendrite length were calculated for the entire dendritic
tree. Due to the relative lack of spines on primary dendrites
(typically, 1 or 2spines/primary dendrite), branch order
analysis was not performed on ﬁrst-order dendrites.
2.4. Statistics. For comparison of both TH and Golgi-
Cox labeling, morphologic data from each mouse were
averaged to provide a single data point used in statistical
comparison. Group diﬀerences for the 5 animals in each
group were analyzed by two-factor (gonadal status and
lesion) analysis of variance (ANOVA). Post hoc comparisons
using the Fisher’s LSD test were conducted when statistically
signiﬁcant diﬀerences (P<. 05) were found.
3.Results
3.1. Striatal TH. Striatal TH immunocytochemistry was
used here as a measure of lesion damage in gonad-intact
andcastratedmales.DamagetomidbrainDAneuronscauses
a loss of striatal DA terminals, which produces equivalent
changesinstriatallevelsofpresynapticdopaminetransporter
and TH [23, 29, 30]. Similar to previous reports by our
lab and others [25, 26, 31, 32], MPTP decreased TH
immunoreactivityinthestriatum(Figures1(a)and1(b),n =
8–10/group). Striatal TH was reduced by 40% after MPTP
(mean gray level 59.4 ± 3.7v e r s u s9 8 .5 ± 3.1 in unlesioned
mice, F(1,31) = 64.883, P<. 05, Figure 1(c)). However,
there was no eﬀect of castration on TH immunoreactivity
and no interaction between MPTP and castration (P>. 05,
Figure 1(c)). This ﬁnding parallels previous studies which
have found no eﬀect of castration on the number of TH-
positive neurons in SNC [33].
3.2. Medium Spiny Neuron Morphology
3.2.1. Spine Density. MSNs have elaborate dendritic arbors
with a high density of dendritic spines (Figure 2). In
saline-treated sham-castrate controls, spines were largely
absent from primary dendrites (1.2 ± 0.2spines/10μm), but
increased onmore distaldendrites(5th-orderdendrites6.8±
0.4spines/10μm). The density of dendritic spines in the
present study (n = 5/group) is comparable to that reported
previously in mice [34–36]. When combining castrated and
gonad-intact mice, MPTP produced a modest butsigniﬁcant
increaseintotalspinedensity(spines/10μm)onMSNs(6.9±
0.1v er s us6.3±0.1in saline-injected castrate andintact mice,
F(1,16) = 10.22, P<. 05, Figure 3(a)). When analyzed
according to branch order, the increase in spine density was
restricted to proximal dendrites (Figure 4(a)). Speciﬁcally,
MPTP-treated mice had a higher spine density on 2nd-order
(5.3±0.3)and 3rd-order (7.1±0.2)dendrites,comparedwith
4.2 ± 0.2a n d6 .5 ± 0.2 in saline-injected mice, respectively
(F(1,16) = 9.659 and 5.700, P<. 05, Figure 4(a)). However,
there was no eﬀect of castration on spine density and no
interaction (P>. 05, Figures 3(a) and 4(a)).
3.2.2. Branch Order. MPTP signiﬁcantly decreased the aver-
age highest branch order (3.9 ± 0.1) compared to saline-
injected males (4.3 ± 0.1, F(1,16) = 4.595, P<. 05,
Figure 3(b)). As with other measures of overall neuronal
morphology, castration was without eﬀect and there was no
interaction (Figure 3(b)).
3.2.3. Dendritic Length. There was no eﬀect of MPTP on
total dendrite length (402.0±17.4μmversus415.5±20.2μm
in saline-injected mice, P>. 05, Figure 3(c)). However,
in parallel to the increase in spine density, we observed
a selective increase in dendritic length after MPTP on
2nd-order dendrites (80.2 ± 6.8μmv e r s u s6 1 .6 ± 4.6μm
in saline-injected mice, F(1,16) = 4.796, P<. 05,
Figure 4(b)). Castration had no eﬀect on total dendritic
length. However, castrated mice had a prominent reduction
in dendritic length of distal dendrites. Speciﬁcally, 5th-order
dendritic length was signiﬁcantly reduced in castrated mice
(78.9±14.8μm) compared with gonad-intact males (138.3±
13.2μm, F(1,16) = 6.659, P<. 05, Figure 4(b)). There was
no interaction between MPTP treatment and gonadectomy
(Figures 3(c) and 4(b)).Parkinson’s Disease 5
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Figure 2: Golgi stained MSNs. Photomicrograph of a representative Golgi-impregnated medium spiny neuron with high-magniﬁcation
inserts of a primary dendritic branch and ﬁfth-order dendritic branch (a) and corresponding neurolucida tracing (b). Scale bar = 10 μm.
4.Discussion
The current study used the MPTP mouse model of PD to
investigate the eﬀects of castration on dopamine-depleting
lesions of the nigrostriatal system. MPTP decreased striatal
TH immunoreactivity, reduced the average highest branch
order on MSNs, and increased proximal spine density.
Separately, castration reduced dendritic length of distal
dendrites. We predicted that testosterone would act as a
neuroprotectant to attenuate the eﬀects of MPTP and that
castrated mice would have increased nigrostriatal damage
after MPTP compared with gonad-intact mice. However,
there was no interaction between gonadal hormone status
and MPTP, suggesting that testosterone does not attenuate
the neurotoxic eﬀects of MPTP in the nigrostriatal system of
males.
The current study used a well-established lesioning
protocol [22, 23] that produced a moderate lesion, as meas-
ured by TH immunostaining. This is relevant to the study
of how gonadal steroid hormones act on the nigrostri-
atal system because the neuroprotective eﬀects of gonadal
hormones are likely to be evident earlier in PD. For ex-
ample, PD symptom severity is sexually dimorphic in early
stages of the disease, with women experiencing less severe
motor impairments [4, 37, 38]. This has been attributed,
i np a r t ,t ot h en e u r o p r o t e c t i v ee ﬀects of estrogen on the
nigrostriatal system. In later stages of PD, sex diﬀerences
are not reported, presumably because severe nigrostriatal
degeneration obscures the eﬀects of neuroprotective factors,
includingestrogen.Thisisparalleledinanimalstudies,where
moderatelesionsdonotoverwhelm thepotentialforgonadal
hormonestoattenuatethenigrostriatal response toMPTP.In
6-OHDA- lesioned rats, Gillies et al. [21]h a v ed e m o n s t r a t e d
sex diﬀerences with small doses of 6-OHDA that disappear
with larger doses. Using MPTP, our laboratory has demon-
strated sex diﬀerences in motor impairments after relatively
small lesions [39]. Even so, in the current study, castration
did not alter the morphologic response to MPTP. Larger
lesionsshouldproduceamoredramaticdepletionofTH,but
seem unlikely to reveal an interaction with castration.
Nonetheless, our results do demonstrate a broad impact
of MPTP on basal ganglia circuitry. Although MPTP
selectively kills dopamine-producing neurons of SNC, its
eﬀects are not limited to dopaminergic neurons themselves.
In fact, morphological eﬀects of MPTP were observed on
eﬀerent targets in the striatum. Speciﬁcally, MPTP increased
dendritic spine density on proximal dendrites of striatal
MSNs. This result was initially surprising because loss of
dopaminergic input to MSNs is expected to reduce spine
density, at least as demonstrated in vitro [34, 40]. Impor-
tantly, the increased spine density observed in our study was
restricted to proximal dendrites. Proximal MSN dendrites
receive synaptic inputs from within the striatum, while distal
dendrites receive extrinsic inputs from the cortex and SNC
[41]. This suggests that the increase in proximal dendritic
spine density after MPTP is driven by intrinsic striatal
neurons, rather than dopaminergic neurons of SNC. This
may reﬂect a compensatory reaction to dopamine depletion
and demonstrates the dynamics of spine morphology with
degree of lesion, model, and time postlesion.
Striatal MSNs receive a variety of aﬀerent inputs which
includeglutamatergicinputsfromcortexaswellasdopamin-
ergicprojectionsfromSNC.Interestingly,MSNspinedensity
is increased after methamphetamine, which also depletes
striatal dopamine [42]. However, the methamphetamine-
induced increase in spine density is selective to distal den-
drites [43–45], while the eﬀect that we observed occurred
proximally. Given the importance of dopaminergic pro-
jections to the striatum, the absence of MPTP-induced6 Parkinson’s Disease
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Figure 3: Neuronal morphology totals. Total spine density (a), average highest branch order (b), and total dendrite length (c) in saline-
injected (unshaded panel) and MPTP-treated (shaded panel) gonad-intact (black bars) and orchidectomized (white bars) male mice (n =
5mice/group). Bars represent an eﬀect of MPTP (P<. 05). OrchX: orchidectomized; Sham: sham-orchidectomized.
structural changes to MSN distal dendritic spines is indeed
unexpected.
The absence of MPTP-induced structural changes to dis-
tal dendrites may relate to the distribution of striatal MSNs
and the heterogeneity of striatal structure. MSNs represent
a heterogeneous population comprised of both D1 receptor-
containing neurons of the direct, striatonigral pathway and
D2 receptor-containing neurons of the indirect, striatopal-
lidal pathway [41]. The indirect pathway has also been
implicated behaviorally, with D2 receptor knockout mice
exhibiting PD-like akinesia and bradykinesia [46]. Behav-
ioral deﬁcits in D1 receptor knockout mice are minimal [47]
or absent [48]. Recently, Day et al. [34]d e m o n s t r a t e da
selective eﬀectofdopamine-depletinglesions onD2receptor
containing MSNs using 6-OHDA. Therefore, it is possible
that MPTP-induced spine changes are also conﬁned to the
D2 receptor-containing subpopulation of MSNs.
The other key observation from our study was that
castrated and gonad-intact males had the same response to
MPTP, suggesting that testosterone fails to protect against
MPTP-induced neuronal damage. Initially, we postulated
that testosterone would be neuroprotective in males, similar
to the eﬀects of estrogen in females. This is because testos-
terone can be converted to estrogen and because PD occurs
most often in older men whose endogenous androgens are
in decline. Although our hypothesis was not supported,Parkinson’s Disease 7
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Figure 4: Branch order totals. Spine density (a) and dendritic length (b) for ﬁrst- to ﬁfth-order branches in striatal medium spiny neurons
(n = 5mice/group). Saline-injected mice include gonad-intact (black bars) and orchidectomized (white bars) males. MPTP-treated mice
include gonad-intact(dark gray bars) and orchidectomized (light graybars) males.Bars represent an eﬀect of MPTP (P<. 05),and asterisks
represent an eﬀect of gonadectomy (P<. 05). Abbreviations: OrchX, orchidectomized; Sham, sham-orchidectomized.
our ﬁndings are in agreement with previous studies which
found no eﬀect of castration on striatal dopamine loss
after MPTP [18] or on TH neurons in SNC after 6-OHDA
[33]. In addition, studies using methamphetamine, which
also depletes striatal dopamine, have shown that dopamine
depletion after methamphetamine as well as amphetamine-
induced stereotyped behaviors are similar in gonad-intact
and castrated animals [49–52]. Interestingly, other studies
have reported that testosterone increases neurotoxicity after
dopamine-depleting lesions [13, 21, 53]. Due to the tremen-
dous variability among published studies, these results are
diﬃcult to interpret. However, testosterone does not appear
to have neuroprotective eﬀects in the male nigrostriatal
system.
Despite having no eﬀecton MPTP-induced morphologic
changes, castration decreased MSN dendritic length, but this
eﬀect was restricted to the distal branches of the dendritic
tree. These eﬀects of castration suggest that testosterone
promotes dendritic growth in striatal MSNs. This raises
an important question. How does testosterone promote
growth of distal dendrites, but fail to attenuate MPTP-
induced structural remodeling? To understand this issue,
it is important to understand how hormones modulate
neuronal plasticity, where hormones act in relation to the
striatum and, in the case of testosterone, whether they act
via androgenic or estrogenic mechanisms.
In hormone-sensitive areas of the brain, testosterone-
driven changes in structural morphology are driven by
classical hormone receptors for androgen or estrogen. For
example, castration decreases dendritic branching in the
posterior medial amygdala (MeP) and medial preoptic area
(MPOA), and reduces spine density on hippocampal CA1
neurons in adult rodents [31, 54, 55]. The ﬁndings in the
current study are similar. However, while MeP, MPOA and
CA1 each contains an abundance of classical receptors for
both androgens and estrogen, the male mouse striatum is
largely devoidofclassical hormonereceptors[56]. Moreover,
classical hormone receptors are also sparse in the major
dopaminergic input to MSN dendrites from SNC [56].
Although previous studies in rats and mice have found some
evidence of AR and ER in SNC [56–58], it appears that few
steroid-sensitive neurons are TH-positive and project to the
striatum [56, 58].This relativeabsence ofhormone receptors
severely limits the ability of testosterone to exert direct or
indirect eﬀects on MSN dendrites via classical mechanisms.
It is more likely that testosterone acts through nonclassical
mechanisms to drive changes in the striatum, as suggested
previously [56, 59]. The present results extend this potential
mechanism to include morphologic changes as well.
In the brain, testosterone can act as an androgen, but it
can also act via estrogenic mechanisms after aromatization.
The ability of gonadal hormones to attenuate nigrostriatal
neurotoxicity is largely attributed to estrogen, which is
neuroprotective in the female. In animal models, estrogen
attenuates striatal dopamine depletion [9, 60, 61]a n dp a r -
tially prevents the loss of striatal TH immunoreactivity [14,
62] after MPTP. Indeed, experimental evidence has shown
that estrogen also protects against nigrostriatal degeneration
in the male striatum. However, while circulating estrogen
is abundant in females, striatal estrogen available in males
is minimal due to the low levels of aromatase in the
striatum [63–66]. Therefore, the inability of testosterone8 Parkinson’s Disease
to act through estrogenic mechanisms eﬀectively prevents
hormone-driven neuroprotection in the striatum. However,
it does not inﬂuence theneurotrophic actions of testosterone
on MSN distal dendrites, which likely occur via androgenic
mechanisms.
Clinically, the actions of gonadal steroid hormones in
the nigrostriatal system are important because estrogen
is thought to be neuroprotective in several neurological
disorders, including Parkinson’s disease. In fact, women are
more likely to develop PD after hysterectomy or menopause,
when endogenous estrogen is eliminated [67, 68]. One of
the potential beneﬁts of hormone replacement therapy on
postmenopausal women is the potential to delay the onset
and/or decrease the severity of neurodegenerative disease.
Men also experience a loss of testosterone with age, albeit
less severe than the complete loss of gonadal steroids in the
female. Although androgen replacement therapy is available
for men with hypoandrogenism, the results of the current
study suggest that androgen replacement will not attenuate
nigrostriatal neurodegeneration in the male.
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